BeyondSpring Presents Plans for 442-Patient Phase 3 Plinabulin Trial in Post-ICI Lung Cancer

• BeyondSpring plans to start its 442-patient DUBLIN-4 confirmatory Phase 3 trial of plinabulin in 2026-2027.
• The trial compares plinabulin with docetaxel against docetaxel alone in post-immunotherapy, driver-negative, non-squamous lung cancer.
• Overall survival is the primary endpoint; interim analysis is expected in 2028 following 221 progression-free survival events.
• Prior DUBLIN-3 data showed median survival of 11.37 months versus 8.81 months in non-squamous patients, with a 0.72 hazard ratio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief on October 25, 2026, and is solely responsible for the information contained therein.